Irene Voo, MD
Ophthalmology · Las Vegas, NVNPI 1215981584
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 60 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AbbVie at 52.1% of the total. 2025 is the largest year on record at $410, more than ten times the $19 reported in 2020. That places this record below the midpoint for ophthalmology clinicians in NV, where the typical reported total is $1,540.
Across 60 payments — averaging $19.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$618
- Genentech USA, Inc.$259
- Astellas Pharma US Inc$182
- Regeneron Healthcare Solutions, Inc.$68
- Carl Zeiss Meditec AG$19
- Apellis Pharmaceuticals, Inc.$16
- plus $25 from 2 others
What the payments were for
- Food & beverage$1,15297%
- Education$151%
- Gifts$192%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 31 | $618 |
| Genentech USA, Inc. | 14 | $259 |
| Astellas Pharma US Inc | 8 | $182 |
| Regeneron Healthcare Solutions, Inc. | 3 | $68 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Apellis Pharmaceuticals, Inc. | 1 | $16 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $13 |
| Alimera Sciences, Inc. | 1 | $11 |
How this compares
$1,186 in reported general payments places this provider in the 40th percentile of 121 ophthalmology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 83 | $5,946 |
| ValacyclovirValacyclovir Hcl | 27 | $1,701 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 47 | $1,022 |
| Dorzolamide Hcl | 24 | $340 |
| Latanoprost | 31 | $340 |
| Ketorolac Tromethamine | 12 | $193 |
| Timolol Maleate | 11 | $182 |
| Prednisone | 13 | $111 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Las Vegas
- Eva LiangLas Vegas$496K
- Steven LeibowitzLas Vegas$147K
- Wonchon LinLas Vegas$43K
- Ravindranath ReddyLas Vegas$30K
- Emily SchorrLas Vegas$17K
- Frank LeeLas Vegas$12K
- Tigran KostanyanLas Vegas$11K
- Tushina ReddyLas Vegas$11K
- Kent WellishLas Vegas$10K
- Eissa HannaLas Vegas$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.